Probing chemical reduction in a cobalt(III) complex as a viable route for the inhibition of the 20S proteasome

Tomco, Dajena; Xavier, Fernando R.; Allard, M.; Verani, Cláudio N.

doi:10.1016/j.ica.2012.06.020

Cited by 12 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…who studied Co(L NN′O ) x complexes (L NN′O = 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol) [40,41*]. These complexes are thought to inhibit proteasomes through ligand exchange with amino acid residues in the active site.…”

Section: Bioreductive Cobalt Complexesmentioning

confidence: 99%

“…The authors postulated that the higher lability of the Co(II) complex results in rapid degradation in biological environments whereas the stability of the inert Co(III) complex offers improved bioavailability. Consequently, the substitutional inertness facilitates intracellular activation of the Co(III) complex following reduction [41*]. The feasibility of this concept was tested by examining the LMCT absorption band of the Co(III) complex.…”

Section: Bioreductive Cobalt Complexesmentioning

confidence: 99%

“…A) Co(III)(L NN′O) 2 undergoes reduction to the more labile Co(II) counterpart to yield an active proteasome inhibitor [40,41*]. In the presence of the reducing agent ascorbic acid, one of the L NN′O ligands of Co(III)(L NN′O) 2 is lost and replaced by a solvent (DMF) molecule, as identified by mass spectrometry.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Cobalt derivatives as promising therapeutic agents

Heffern

Yamamoto²,

Holbrook³

et al. 2013

Current Opinion in Chemical Biology

159

View full text Add to dashboard Cite

Inorganic complexes are versatile platforms for the development of potent and selective pharmaceutical agents. Cobalt possesses a diverse array of properties that can be manipulated to yield promising drug candidates. Investigations into the mechanism of cobalt therapeutic agents can provide valuable insight into the physicochemical properties that can be harnessed for drug development. This review presents examples of bioactive cobalt complexes with special attention to their mechanisms of action. Specifically, cobalt complexes that elicit biological effects through protein inhibition, modification of drug activity, and bioreductive activation are discussed. Insights gained from these examples reveal features of cobalt that can be rationally tuned to produce therapeutics with high specificity and improved efficacy for the biomolecule or pathway of interest.

show abstract

Section: Bioreductive Cobalt Complexesmentioning

confidence: 99%

Section: Bioreductive Cobalt Complexesmentioning

confidence: 99%

See 1 more Smart Citation

Cobalt derivatives as promising therapeutic agents

Heffern

Yamamoto²,

Holbrook³

et al. 2013

Current Opinion in Chemical Biology

159

View full text Add to dashboard Cite

show abstract

Recent Advances in Acid–Base and Solvation Properties of Metal Phenolates

Bastos

Machado

2017

Patai's Chemistry of Functional Groups

View full text Add to dashboard Cite

This chapter is an update of a recent review on the acid–base chemistry and solvation properties of metal phenolates. After a brief introduction on the physicochemical properties of metal phenolates, the interaction between phenolate ligands and metal Lewis acids is discussed. Examples of solvent effects on the acid–base properties, structure, and chemical reactivity are presented. Furthermore, the interaction of multidentate phenolic ligands and metal cations is highlighted because of their relevance in transition‐metal coordination chemistry, catalyst development, metalloenzyme mimicry, cytotoxicity, and magnetic properties.

show abstract